Transient Receptor Potential Melastatin 3 (TRPM3) ion channel has been suggested as a potential biomarker and target for therapeutics in people with ME/CFS, supported by a series of publications reporting genetic and protein changes. The gene discussed is TRPM3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.